Patents by Inventor Yuntao Wu

Yuntao Wu has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240108687
    Abstract: The present disclosure relates to combinations and formulations of actin-based peptides with molecules to enhance the bioactivities of actin-based peptides for enhancing their abilities for modulating actin-related cellular bioactivity and cellular susceptibility to viral infection.
    Type: Application
    Filed: February 14, 2022
    Publication date: April 4, 2024
    Applicant: Virongy L.L.C.
    Inventor: Yuntao WU
  • Patent number: 11922597
    Abstract: The present disclosure relates to a video processing method and apparatus, a readable medium, and an electronic device, which relate to the technical field of image processing; the method includes: preprocessing a target video to obtain a plurality of target image frames of the target video; identifying a position of a designated object in each of the target image frames; and determining a reserved image frame from the target image frames based on the position of the designated object in each of the target image frames, the reserved image frame being used to indicate a cropping on image frames before the reserved image frame in the target video.
    Type: Grant
    Filed: November 16, 2021
    Date of Patent: March 5, 2024
    Assignee: BEIJING YOUZHUJU NETWORK TECHNOLOGY CO., LTD.
    Inventors: Hao Wu, Yuntao Ma, Changhu Wang
  • Patent number: 11850281
    Abstract: Persistence of HIV in anatomic sanctuary sites such as the brain prevents viral eradication. Although combination antiretroviral therapy (cART) inhibits viral replication to undetectable level by standard clinical assay, it does not selectively eliminate virus reservoirs. To target HIV reservoirs, the present inventor developed an HIV Rev-dependent lentiviral vector carrying a series of therapeutic genes, such as diphtheria toxin, anthrolysin O from Bacillus anthracis, human TRAF6, or the herpes simplex 1 virus thymidine kinase gene (HSV-tk). The present disclosure provides the Rev-dependent vectors for targeting viral reservoir in a SIV/rhesus macaque model. SIV-infected rhesus macaques were first treated with cART for over 6 months starting 12 weeks post infection, followed by injections with viral particles assembled from a SIV Rev-dependent vector carrying HSV-tk.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: December 26, 2023
    Assignee: George Mason Research Foundation, Inc.
    Inventor: Yuntao Wu
  • Patent number: 11732042
    Abstract: The present disclosure relates to composition and methodology for using the CD2 receptor to block viral replication, such as HIV-1 infection. In one embodiment, viral target cells such as blood CD4 T cells can be rendered resistant to HIV through stimulation of the CD2 receptor with either an antibody, a ligand, or a small molecule that binds to the CD2 receptor. Pre-stimulation of CD2 can be used to enhance the anti-HIV immunity and used to promote immune response from HIV infection or from an anti-HIV vaccine.
    Type: Grant
    Filed: October 10, 2018
    Date of Patent: August 22, 2023
    Inventors: Yuntao Wu, Hong Shang
  • Publication number: 20230235219
    Abstract: The present invention provides a low-dimensional perovskite-structured metal halide and a preparation method and application thereof. The general formulas of the compositions of the low-dimensional perovskite-structured metal halide are AB2X3, A2BX3, and A3B2X5; wherein, A is at least one of Li, Na, K, Rb, Cs, In, and Tl; B is at least one of Cu, Ag, and Au; and X is at least one of F, Cl, Br, and I.
    Type: Application
    Filed: June 10, 2021
    Publication date: July 27, 2023
    Inventors: Yuntao WU, Shuangliang CHENG, Qian WANG, Jian SHI, Huanying LI, Guohao REN
  • Publication number: 20230193127
    Abstract: Codoped lutetium-based oxyorthosilicate scintillators (e.g., lutetium oxyorthosilicase (LSO) and lutetium-ytrrium oxyorthosilicate (LYSO) scintillators) codoped with transition metal ions (e.g., Cu2+) are described. The codoping can alter one or more optical and/or scintillation property of the scintillator material. For example, the codoping can increase scintillation light yield and/or decrease scintillation decay time. Radiation detectors comprising the scintillators, methods of detecting high energy radiation using the radiation detectors, and methods of altering one or more scintillation and/or optical properties of a lutetium-based oxyorthosilicate scintillator are also described.
    Type: Application
    Filed: December 16, 2022
    Publication date: June 22, 2023
    Inventors: Yuntao Wu, Merry A. Koschan, Charles L. Melcher
  • Patent number: 11560515
    Abstract: Codoped lutetium-based oxyorthosilicate scintillators (e.g., lutetium oxyorthosilicase (LSO) and lutetium-ytrrium oxyorthosilicate (LYSO) scintillators) codoped with transition metal ions (e.g., Cu2+) are described. The codoping can alter one or more optical and/or scintillation property of the scintillator material. For example, the codoping can increase scintillation light yield and/or decrease scintillation decay time. Radiation detectors comprising the scintillators, methods of detecting high energy radiation using the radiation detectors, and methods of altering one or more scintillation and/or optical properties of a lutetium-based oxyorthosilicate scintillator are also described.
    Type: Grant
    Filed: April 3, 2020
    Date of Patent: January 24, 2023
    Assignee: University of Tennessee Research Foundation
    Inventors: Yuntao Wu, Merry A. Koschan, Charles L. Melcher
  • Patent number: 11474264
    Abstract: Eutectic lithium chloride-cerium chloride (LiCl—CeCl3) compositions are described. An exemplary eutectic composition has about 75 mole % LiCl and about 25 mole % CeCl3. The eutectic compositions can have optical and/or scintillation properties. Also described are methods of preparing the eutectic compositions as well as methods of using radiation detectors including the eutectic compositions in the detection of radiation, including thermal neutrons.
    Type: Grant
    Filed: February 26, 2021
    Date of Patent: October 18, 2022
    Assignee: University of Tennessee Research Foundation
    Inventors: Mariya Zhuravleva, Yuntao Wu, Charles L. Melcher
  • Patent number: 11473064
    Abstract: Timely development of vaccines and antiviral drugs is critical to control the COVID-19 pandemic. Current methods for quantifying vaccine-induced neutralizing antibodies involve the use of pseudoviruses, such as the SARS-CoV-2 spike protein (S) pseudotyped lentivirus. However, these pseudoviruses contain structural proteins foreign to SARS-CoV-2, and require days to infect and express reporter genes. Here, the present application discloses composition and methodology for making and using a new hybrid alphavirus-SARS-CoV-2 (Ha-CoV-2) particle for rapid and accurate quantification of neutralization antibodies and viral variants.
    Type: Grant
    Filed: October 19, 2021
    Date of Patent: October 18, 2022
    Assignee: George Mason Research Foundation, Inc.
    Inventors: Brian Hetrick, Yuntao Wu
  • Patent number: 11382967
    Abstract: Embodiments relate to methods comprising expressing or overexpressing P-selectin glycoprotein ligand-1 (PSGL-1) in human immunodeficiency virus (HIV) producing cells; isolating HIV particles from the HIV producing cells; and preparing the isolated HIV particles as a HIV vaccine. Embodiments relate to systems comprising a HIV vaccine comprising live attenuated, inactivated, or non-infectious HIV particles. Embodiments relate to systems capable of performing a method comprising administering a vaccine comprising live attenuated, inactivated, or non-infectious HIV particles to a subject in need of the vaccine; and treating or preventing one or more disease states in the subject resulting from HIV infection.
    Type: Grant
    Filed: June 9, 2020
    Date of Patent: July 12, 2022
    Assignee: George Mason University
    Inventors: Yuntao Wu, Yajing Fu, Deemah Dabbagh, Zheng Zhou
  • Patent number: 11377499
    Abstract: The present disclosure provides a method of restoring immune reconstitution, immune control of viremia, and one or more T cell functions in a subject infected with HIV. The method includes administering to the subject infected with HIV an agent that targets the cofilin pathway.
    Type: Grant
    Filed: November 27, 2018
    Date of Patent: July 5, 2022
    Assignee: George Mason University
    Inventor: Yuntao Wu
  • Publication number: 20220119776
    Abstract: Timely development of vaccines and antiviral drugs is critical to control the COVID-19 pandemic. Current methods for quantifying vaccine-induced neutralizing antibodies involve the use of pseudoviruses, such as the SARS-CoV-2 spike protein (S) pseudotyped lentivirus. However, these pseudoviruses contain structural proteins foreign to SARS-CoV-2, and require days to infect and express reporter genes. Here, the present application discloses composition and methodology for making and using a new hybrid alphavirus-SARS-CoV-2 (Ha-CoV-2) particle for rapid and accurate quantification of neutralization antibodies and viral variants.
    Type: Application
    Filed: October 19, 2021
    Publication date: April 21, 2022
    Inventors: Brian HETRICK, Yuntao WU
  • Patent number: 11230667
    Abstract: Codoped rare earth garnet-type oxide scintillators are described. More particularly, the scintillators include lutetium yttrium aluminum garnet (LuYAG)-type materials that are doped with an activator, such as praseodymium, and codoped with a monovalent cation, such as lithium. Radiation detectors comprising the scintillators, methods of detecting higher energy radiation using the scintillators, and methods of preparing the scintillators and altering scintillator properties are also described.
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: January 25, 2022
    Assignee: University of Tennessee Research Foundation
    Inventors: Camera Janelle Foster, Yuntao Wu, Merry A. Koschan, Charles L. Melcher
  • Patent number: 11116833
    Abstract: Embodiments relate to expressing or overexpressing P-selectin glycoprotein ligand-1 (PSGL-1) in human immunodeficiency virus (HIV) producing cells; isolating HIV particles from the HIV producing cells; and preparing the isolated HIV particles as a HIV vaccine. Embodiments relate to a HIV vaccine comprising live attenuated, inactivated, or non-infectious HIV particles. Embodiments relate to systems performing a method comprising administering a vaccine comprising live attenuated, inactivated, or non-infectious HIV particles to a subject in need of the vaccine; and treating or preventing one or more disease states in the subject resulting from HIV infection.
    Type: Grant
    Filed: February 8, 2019
    Date of Patent: September 14, 2021
    Assignee: George Mason University
    Inventors: Yuntao Wu, Yajing Fu, Deemah Dabbagh, Zheng Zhou
  • Publication number: 20210270980
    Abstract: Eutectic lithium chloride-cerium chloride (LiCl—CeCl3) compositions are described. An exemplary eutectic composition has about 75 mole % LiCl and about 25 mole % CeCl3. The eutectic compositions can have optical and/or scintillation properties. Also described are methods of preparing the eutectic compositions as well as methods of using radiation detectors including the eutectic compositions in the detection of radiation, including thermal neutrons.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 2, 2021
    Inventors: Mariya Zhuravleva, Yuntao Wu, Charles L. Melcher
  • Publication number: 20210261635
    Abstract: Compositions and methods for using actin-based peptides to modulate cellular bioactivity, including modulation of cellular susceptibility to intracellular pathogens, such as bacteria and viruses.
    Type: Application
    Filed: May 11, 2021
    Publication date: August 26, 2021
    Inventor: Yuntao Wu
  • Publication number: 20210236583
    Abstract: The present disclosure relates to the design and method for targeting the renin-angiotensin system (RAS) for therapeutics of lung diseases, particularly environment- and pathogen-induced lung injury. Provided herein are design, methodology, compositions, and the like for such for restoring the regulatory balance the RAS system for the management of lung diseases.
    Type: Application
    Filed: February 1, 2021
    Publication date: August 5, 2021
    Inventor: Yuntao WU
  • Publication number: 20210179712
    Abstract: The present disclosure relates to composition and methodology for using the CD2 receptor to block viral replication, such as HIV-1 infection. In one embodiment, viral target cells such as blood CD4 T cells can be rendered resistant to HIV through stimulation of the CD2 receptor with either an antibody, a ligand, or a small molecule that binds to the CD2 receptor. Pre-stimulation of CD2 can be used to enhance the anti-HIV immunity and used to promote immune response from HIV infection or from an anti-HIV vaccine.
    Type: Application
    Filed: October 10, 2018
    Publication date: June 17, 2021
    Inventors: Yuntao WU, Hong SHANG
  • Patent number: 11028138
    Abstract: Compositions and methods for using actin-based peptides to modulate cellular bioactivity, including modulation of cellular susceptibility to intracellular pathogens, such as bacteria and viruses.
    Type: Grant
    Filed: March 1, 2017
    Date of Patent: June 8, 2021
    Inventor: Yuntao Wu
  • Patent number: D1009044
    Type: Grant
    Filed: January 8, 2022
    Date of Patent: December 26, 2023
    Inventor: Yuntao Wu